Difference between revisions of "Part:BBa K218006:Experience"
(→Applications of BBa_K218006) |
(→Applications of BBa_K218006) |
||
| Line 4: | Line 4: | ||
===Applications of BBa_K218006=== | ===Applications of BBa_K218006=== | ||
| − | This signalling circuit encodes the proteins necessary for the V. harveyi signalling cascade. Once suitable expression levels of LuxPQ have been established based on the library of ∆σ70, this circuit will be fully functional. The power of the AI-2 signalling system coupled with a response by using the qrr4 promoter ([[Part: | + | This signalling circuit encodes the proteins necessary for the V. harveyi signalling cascade. Once suitable expression levels of LuxPQ have been established based on the library of ∆σ70, this circuit will be fully functional. The power of the AI-2 signalling system coupled with a response by using the qrr4 promoter ([[Part:BBa_K131017]]) in a laboratory strain of E. coli lies within the principle of QS and coordinating bacterial behaviour. The E. coli will be able to express a gene with a desired function at high population densities simply if this gene is cloned downstream of the qrr4 promoter. This engineered system will prove quite versatile will respect to the output from AI-2 signalling. |
The usefulness of AI-2 signalling in E. coli stretches far beyond the ability to clone in a gene of interest to express in high population densities. This safe, non-pathogenic, laboratory E. coli model of AI-2 signaling will contribute to the understanding of QS systems used by pathogenic bacteria to induce virulence. Periplasmic protein LuxP has been identified as a ribose-binding protein and its crystal structure has been determined along with important amino acids for AI-2 binding. Although this allows for the investigation of other LuxP-binding molecules in silico, the presence of AI-2 signalling in E. coli will allow for in vitro investigations of activating and inactivating ligands. With this comes the development of novel therapeutics aimed at attenuating QS and thus virulence induction in pathogenic bacteria by, for example, synthesizing a drug capable of competitively inhibiting the AI-2 binding site on LuxP. Targeting and preventing QS is particularly appealing considering the emergence of increasingly antibiotic resistant bacteria. | The usefulness of AI-2 signalling in E. coli stretches far beyond the ability to clone in a gene of interest to express in high population densities. This safe, non-pathogenic, laboratory E. coli model of AI-2 signaling will contribute to the understanding of QS systems used by pathogenic bacteria to induce virulence. Periplasmic protein LuxP has been identified as a ribose-binding protein and its crystal structure has been determined along with important amino acids for AI-2 binding. Although this allows for the investigation of other LuxP-binding molecules in silico, the presence of AI-2 signalling in E. coli will allow for in vitro investigations of activating and inactivating ligands. With this comes the development of novel therapeutics aimed at attenuating QS and thus virulence induction in pathogenic bacteria by, for example, synthesizing a drug capable of competitively inhibiting the AI-2 binding site on LuxP. Targeting and preventing QS is particularly appealing considering the emergence of increasingly antibiotic resistant bacteria. | ||
Revision as of 03:25, 22 October 2009
This experience page is provided so that any user may enter their experience using this part.
Please enter
how you used this part and how it worked out.
Applications of BBa_K218006
This signalling circuit encodes the proteins necessary for the V. harveyi signalling cascade. Once suitable expression levels of LuxPQ have been established based on the library of ∆σ70, this circuit will be fully functional. The power of the AI-2 signalling system coupled with a response by using the qrr4 promoter (Part:BBa_K131017) in a laboratory strain of E. coli lies within the principle of QS and coordinating bacterial behaviour. The E. coli will be able to express a gene with a desired function at high population densities simply if this gene is cloned downstream of the qrr4 promoter. This engineered system will prove quite versatile will respect to the output from AI-2 signalling.
The usefulness of AI-2 signalling in E. coli stretches far beyond the ability to clone in a gene of interest to express in high population densities. This safe, non-pathogenic, laboratory E. coli model of AI-2 signaling will contribute to the understanding of QS systems used by pathogenic bacteria to induce virulence. Periplasmic protein LuxP has been identified as a ribose-binding protein and its crystal structure has been determined along with important amino acids for AI-2 binding. Although this allows for the investigation of other LuxP-binding molecules in silico, the presence of AI-2 signalling in E. coli will allow for in vitro investigations of activating and inactivating ligands. With this comes the development of novel therapeutics aimed at attenuating QS and thus virulence induction in pathogenic bacteria by, for example, synthesizing a drug capable of competitively inhibiting the AI-2 binding site on LuxP. Targeting and preventing QS is particularly appealing considering the emergence of increasingly antibiotic resistant bacteria.
User Reviews
UNIQ8a6f552b44a49704-partinfo-00000000-QINU UNIQ8a6f552b44a49704-partinfo-00000001-QINU